Fast, flexible, with improved precision, greater capacity, and more sustainable energy consumption: these are the main characteristics of the new Illumina MiSeq i100, which is now part of the centre’s technological equipment. With this incorporation, made possible by funding from the Josep Carreras Foundation Against Leukaemia, research groups within or outside the Institute will have access to the latest chemical synthesis (SBS) sequencing technology, which guarantees much more robust results and is adaptable to a wide variety of experimental projects.

The MiSeq i100 is particularly well-suited for medium-scale projects, with a capacity of up to 200 million paired-end reads per experiment. Furthermore, it offers faster and more cost-effective performance compared to the MiSeqDx, which remains essential for targeted sequencing of DNA libraries in both research and clinical diagnostics.

The complementarity between the two systems significantly expands the range of available applications: targeted resequencing, sequencing of small genomes and amplicons, metagenomics, RNA-seq experiments, library quality control, and other genomic analysis protocols. This versatility addresses the growing needs of research groups working on complex, high-impact biomedical projects.

This technological upgrade reinforces the IJC's commitment to cutting-edge research. The new tools are especially relevant for advancing the study of leukaemia and other haematological malignancies, where identifying genetic alterations remains key to discovering new therapeutic targets and improving patient prognosis.

With this addition, the Institute strengthens its commitment to providing the scientific community with the most advanced resources to drive new avenues of research and, ultimately, contribute to achieving its mission: that leukaemia and other blood cancers will one day be 100% curable.